|
Market Closed -
Nasdaq
21:00:00 01/09/2026 BST
|
5-day change | 1st Jan Change | ||
| 0.8610 USD | -0.36% |
|
-9.84% | +24.30% |
| 08-17 | Cellution Biologics Llc completed the acquisition of SimpliDerm human acellular dermal matrix business of Elutia Inc. for $11 million. | CI |
| 08-13 | Elutia Inc., Q2 2026 Earnings Call, Aug 13, 2026 |
| Market Cap | 38.13M 32.89M 30.94M 28.21M 52.97M 3.62B 53.36M 367M 142M 1.84B 143M 140M 6.11B | P/E 2026 * |
-1.37x | P/E 2027 * | -1.59x |
|---|---|---|---|---|---|
| Enterprise Value | 38.13M 32.89M 30.94M 28.21M 52.97M 3.62B 53.36M 367M 142M 1.84B 143M 140M 6.11B | EV / Sales 2026 * |
5.08x | EV / Sales 2027 * | 8.87x |
| Free-Float |
85.26% | Yield 2026 * |
-
| Yield 2027 * | - |
Last Transcript : Elutia Inc.
| 1 day | -0.36% | ||
| 1 week | -9.84% | ||
| Current month | -0.36% | ||
| 1 month | +0.49% | ||
| 3 months | -25.78% | ||
| 6 months | -25.13% | ||
| Current year | +24.30% |
| 1 week | 0.84 |  | 1.05 |
| 1 month | 0.76 | | 1.05 |
| Current year | 0.6 | | 1.38 |
| 1 year | 0.5 | | 2.38 |
| 3 years | 0.5 | | 5.24 |
| 5 years | 0.5 | | 9.76 |
| 10 years | 0.5 | | 18.2 |
| Manager | Title | Age | Since |
|---|---|---|---|
| Chief Operating Officer | 52 | - | |
Charles Mills
CEO | Chief Executive Officer | 54 | 20/06/2022 |
Matthew Ferguson
DFI | Director of Finance/CFO | 58 | 27/09/2020 |
| Director | Title | Age | Since |
|---|---|---|---|
Kevin Rakin
CHM | Chairman | 65 | 31/10/2015 |
Charles Mills
BRD | Director/Board Member | 54 | 31/10/2015 |
Brigid Makes
BRD | Director/Board Member | 70 | 31/08/2020 |
| Date | Insider | Type | Main position | Quantity | % Market Cap. | Importance |
|---|---|---|---|---|---|---|
| 01/06/26 | Don | Founder | -120,000 | 0.2714% | ||
| 01/06/26 | HighCape Partners Management LLC
| Other | Company | 0 | 0% | - |
| 10/03/26 | Exercice | Chief Financial Officer | 30,123 | 0.0747% |
| Change | 5-day change | 1-year change | 3-year change | Capi.($) | ||
|---|---|---|---|---|---|---|
 | -0.36% | -9.84% | -62.24% | -42.60% | 38.27M | |
| +3.10% | -0.56% | +41.87% | -0.32% | 79.79B | |
| +0.43% | +1.89% | -19.06% | -37.01% | 58.85B | |
| +9.93% | +11.07% | +540.39% | +36.44% | 56.03B | |
| +0.13% | -3.37% | -1.24% | +34.14% | 51.26B | |
| +1.49% | -0.68% | +9.33% | +163.89% | 47.68B | |
| -0.28% | -0.95% | +63.39% | -19.20% | 32.01B | |
| +1.45% | -2.32% | +47.75% | +93.72% | 24.98B | |
| -2.12% | +2.11% | +4.90% | +189.46% | 23.05B | |
| +1.69% | +1.19% | +59.26% | +116.16% | 16.31B | |
| Average | +0.39% | -1.84% | +68.44% | +53.47% | 39B | |
| Weighted average by Cap. | +0.68% | -1.51% | +95.33% | +44.59% |
| 2026 * | 2027 * | |
|---|---|---|
| Net sales | 7.5M 6.47M 6.09M 5.55M 10.42M 712M 10.49M 72.1M 28.01M 362M 28.16M 27.55M 1.2B | 4.3M 3.71M 3.49M 3.18M 5.97M 408M 6.02M 41.34M 16.06M 208M 16.14M 15.79M 689M |
| Net income | -27.3M -23.55M -22.15M -20.2M -37.92M -2.59B -38.2M -262M -102M -1.32B -102M -100M -4.37B | -23.6M -20.35M -19.15M -17.46M -32.78M -2.24B -33.02M -227M -88.13M -1.14B -88.6M -86.68M -3.78B |
| Net Debt | - | - |
Employees
26
Sector
Pharmaceuticals
| Date | Price | Change | Volume |
|---|---|---|---|
| 01/09/26 | US$0.8610 | -0.36% | 22,719 |
| 31/08/26 | US$0.8641 | -1.81% | 54,184 |
| 28/08/26 | US$0.8800 | 0.00% | 138,624 |
| 27/08/26 | US$0.8800 | -12.00% | 231,621 |
| 26/08/26 | US$1.000 | -0.99% | 16,285 |
Sell
Buy
Mean consensus
BUY
Number of Analysts
1
Last Close Price
0.8641USD
Average target price
5.000USD
Spread / Average Target
+478.64%
Quarterly revenue - Rate of surprise
- Stock Market
- Stocks
- ELUT Stock
Select your edition
All financial news and data tailored to specific country editions
